These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 27537362)

  • 41. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
    Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
    Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
    Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
    Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.
    Fu Z; Kitagawa Y; Shen R; Shah R; Mehra R; Rhodes D; Keller PJ; Mizokami A; Dunn R; Chinnaiyan AM; Yao Z; Keller ET
    Prostate; 2006 Feb; 66(3):248-56. PubMed ID: 16175585
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
    Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
    Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of doublecortin-like kinase 1 with tumor aggressiveness and poor biochemical recurrence-free survival in prostate cancer.
    Jiang D; Xiao C; Xian T; Wang L; Mao Y; Zhang J; Pang J
    Onco Targets Ther; 2018; 11():1077-1086. PubMed ID: 29535532
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumor Suppressor Role and Clinical Significance of the
    Liang YX; Liang YK; Zou ZH; Zhuo YJ; Ye JH; Zhu XJ; Cai ZD; Lin ZY; Mo RJ; Wu SL; Zhang YQ; Zhong WD
    Dis Markers; 2022; 2022():8724035. PubMed ID: 35548776
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
    Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
    Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
    BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [miR-129 in the diagnosis, treatment and prediction of clinical prognosis of prostate cancer].
    Zhao XD; Tang ZL; Wang ZH; Dong J; Xu S
    Zhonghua Nan Ke Xue; 2022 Nov; 28(11):996-1005. PubMed ID: 37846115
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
    Zhigang Z; Wenlv S
    Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
    Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
    Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
    [TBL] [Abstract][Full Text] [Related]  

  • 52. miR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma.
    Xu S; Yi XM; Zhang ZY; Ge JP; Zhou WQ
    Mol Med Rep; 2016 Dec; 14(6):5025-5032. PubMed ID: 27779679
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of multiple biomarkers for a molecular diagnosis of prostate cancer.
    Landers KA; Burger MJ; Tebay MA; Purdie DM; Scells B; Samaratunga H; Lavin MF; Gardiner RA
    Int J Cancer; 2005 May; 114(6):950-6. PubMed ID: 15609297
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
    Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
    [No Abstract]   [Full Text] [Related]  

  • 55. Increased Id-1 expression is significantly associated with poor survival of patients with prostate cancer.
    Forootan SS; Wong YC; Dodson A; Wang X; Lin K; Smith PH; Foster CS; Ke Y
    Hum Pathol; 2007 Sep; 38(9):1321-9. PubMed ID: 17599389
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.
    Yu L; Toriseva M; Tuomala M; Seikkula H; Elo T; Tuomela J; Kallajoki M; Mirtti T; Taimen P; Boström PJ; Alanen K; Nurmi M; Nees M; Härkönen P
    Int J Cancer; 2016 Jul; 139(1):140-52. PubMed ID: 26891277
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer.
    Schubert M; Spahn M; Kneitz S; Scholz CJ; Joniau S; Stroebel P; Riedmiller H; Kneitz B
    PLoS One; 2013; 8(6):e65064. PubMed ID: 23798998
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue.
    Du Z; Fujiyama C; Chen Y; Masaki Z
    Chin Med J (Engl); 2003 Dec; 116(12):1936-9. PubMed ID: 14687488
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prostate specific G protein coupled receptor is associated with prostate cancer prognosis and affects cancer cell proliferation and invasion.
    Cao W; Li F; Yao J; Yu J
    BMC Cancer; 2015 Nov; 15():915. PubMed ID: 26582057
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.
    Zhong W; Peng J; He H; Wu D; Han Z; Bi X; Dai Q
    Clin Invest Med; 2008; 31(1):E8-E15. PubMed ID: 18312749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.